Andelyn Biosciences, Inc., a pioneering and patient-focused cell and gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered...
Regenerex Pharma, Inc. (OTC: RGPX), a leading innovator in advanced wound closure systems for chronic wounds, today announced that it has entered into a ...
MEDIPAL HOLDINGS CORPORATION (TSE 7459, MEDIPAL) and JCR Pharmaceuticals Co., Ltd. (TSE 4552, JCR) announced that the two companies have signed an exclus...
Ryvu to support BioNTech in the acceleration of site activation and enrollment of patients for multiple of BioNTech’s priority oncology clin...
Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3 In the Phase II KA...
Foresight Diagnostics ("Foresight") announced that it has entered into a limited licensing agreement with Roche Molecular Systems and Roche Sequencing Sy...
Santhera Pharmaceuticals (SIX: SANN) announces the signing of an exclusive agreement with Ikris Pharma Network (Ikris) to manage the distribution of AGAM...
Celaid Therapeutics Inc. ("Celaid") have executed a collaborative research agreement with AGC Inc. ("AGC") to advance iPS cell-derived hematopoietic stem...
AmeriWater, a leading provider of advanced water purification systems for healthcare, is pleased to announce it has signed an agreement with Vizient®...
-Novotech, a globally recognized full-service clinical research organization (CRO), is proud to have partnered with Chia Tai Tianqing Pharmaceutical Grou...
CAGE Bio Inc., a leader in advancing innovative therapies for targeted and localized treatment of immunological skin diseases, today announced it has ent...
MannKind Corporation announced that United Therapeutics Corporation has exercised its option—granted under the companies’ 2018 lic...
Bridge financing of $2.1 million supports initiation of pivotal Phase II study in 140 patients with microsatellite stable metastatic colorectal cancer, a...
Scenic Biotech, a pioneer in modifier therapies for severe diseases, announced a license and research agreement with Alnylam Pharmaceuticals, Inc. (NASDA...
© 2025 Biopharma Boardroom. All Rights Reserved.
